Galcanezumab-induced elevated calcitonin gene-related peptide level in episodic cluster headache

Key Points

• Elevated calcitonin gene-related peptide levels are associated with episodic cluster headache.
• The specific mechanism of action of galcanezumab in this context remains unclear, but it indicates a potential pathway.
• Analysis was performed on patients receiving galcanezumab for cluster headache management.
• Further studies are warranted to explore these neuropeptide interactions in pain pathways.